Neurofilament-light chain (NfL) as a biomarker of response to higher-efficacy disease-modifying therapies

November 22, 2023

Recommend to a Colleague print

 

Includes data on NfL changes after initiation of fingolimod, ofatumumab, ocrelizumab, natalizumab, alemtuzumab and oral cladribine.

11 slides

Download the slide deck

Recommend to a Colleague

Related Posts

• Fluid biomarkers in MS – the year in review
  November 25, 2024
• High-efficacy DMTs in MS – the year in review
  November 14, 2024
• Pregnancy and MS – new data from ECTRIMS
  October 17, 2024
• ECTRIMS update on ofatumumab
  October 11, 2024
• ECTRIMS 2024 HIGHLIGHTS – FRIDAY, SEPTEMBER 20, 2024
  September 20, 2024

Go back to home page